Quick Answer
Both allergy drops (sublingual immunotherapy) and allergy shots (subcutaneous immunotherapy) effectively reduce allergen-driven symptoms by modifying the underlying immune response. Sublingual drops/tablets offer the convenience of home administration and avoid injections. Shots are FDA-approved for custom allergen mixes; sublingual tablets are FDA-approved only for specific allergens (grass, ragweed, dust mites, and peanut).
FDA-Approved Sublingual Options vs Off-Label Drops
In the United States, FDA-approved sublingual allergen immunotherapy (SLIT) currently includes four products: Grastek (Timothy grass pollen), Oralair (5-grass mix), Ragwitek (ragweed pollen), Odactra (house dust mite), and Palforzia (peanut OIT). These products have completed rigorous clinical trials demonstrating safety and efficacy for their specific allergens.
In contrast, sublingual drops (SLIT-drops) using custom-compounded allergen extracts — similar in concept to the standardized tablets but mixed to individual patient sensitivities — are widely used by many allergists in the US but have not received FDA approval. They are dispensed off-label, meaning insurance coverage varies significantly and their efficacy data is less standardized than the approved tablets.
Efficacy Comparison
Meta-analyses comparing SCIT (shots) and SLIT (sublingual) for environmental allergies show that both are significantly more effective than placebo. SCIT generally shows somewhat larger effect sizes in head-to-head studies — particularly for allergic asthma — though both produce meaningful symptom reduction and disease modification. For grass pollen and dust mite allergy, FDA-approved sublingual tablets have strong efficacy data that is competitive with shots for rhinitis outcomes.
The duration of benefit after stopping treatment appears similar between both modalities when full treatment courses are completed (3–5 years). Post-treatment sustained benefit, reduced medication use, and prevention of new sensitizations have been documented with both approaches. Choice between them depends on patient preference, specific allergen, physician experience, and insurance coverage.
Convenience and Safety Comparison
Allergy shots require office visits 1–2 times per week during buildup (4–6 months) and monthly during maintenance (3–5 years). This requires significant patient commitment and time. Sublingual tablets are taken once daily at home after the first dose is supervised in the office — a significant convenience advantage particularly for patients with busy schedules, needle aversion, or limited geographic access to allergy offices.
Both modalities can cause systemic reactions, but SCIT carries a somewhat higher risk of anaphylaxis due to direct injection into the bloodstream circulation. SLIT systemic reactions are less common and less severe because sublingual mucosal allergen absorption is slower. SLIT-related reactions most commonly include oral tingling, lip swelling, and throat itch — managed by antacids (calcium carbonate) or antihistamines.
Key Takeaways
- FDA-approved SLIT tablets exist for grass, ragweed, dust mites, and peanut (Palforzia).
- SCIT (shots) generally has slightly larger effect sizes for allergic asthma; both are superior to placebo.
- SLIT tablets offer home administration convenience after first supervised dose — no weekly office visits.
- SCIT carries slightly higher systemic reaction risk than SLIT due to injection route.
- Both produce 3–5+ years of sustained post-treatment benefit when full courses are completed.
Related Guide
Allergy Treatment Hub →